CN109998113A - A kind of functional food of the probiotics preparation with effect of lowering blood sugar - Google Patents
A kind of functional food of the probiotics preparation with effect of lowering blood sugar Download PDFInfo
- Publication number
- CN109998113A CN109998113A CN201910315091.0A CN201910315091A CN109998113A CN 109998113 A CN109998113 A CN 109998113A CN 201910315091 A CN201910315091 A CN 201910315091A CN 109998113 A CN109998113 A CN 109998113A
- Authority
- CN
- China
- Prior art keywords
- preparation
- functional food
- effect
- bacterium
- blood sugar
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 53
- 239000008280 blood Substances 0.000 title claims abstract description 32
- 210000004369 blood Anatomy 0.000 title claims abstract description 32
- 239000006041 probiotic Substances 0.000 title claims abstract description 24
- 235000018291 probiotics Nutrition 0.000 title claims abstract description 24
- 235000013376 functional food Nutrition 0.000 title claims abstract description 23
- 230000000694 effects Effects 0.000 title claims abstract description 21
- 241000186604 Lactobacillus reuteri Species 0.000 claims abstract description 14
- 240000001046 Lactobacillus acidophilus Species 0.000 claims abstract description 13
- 241000186606 Lactobacillus gasseri Species 0.000 claims abstract description 13
- 229940001882 lactobacillus reuteri Drugs 0.000 claims abstract description 11
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 claims abstract description 10
- 229940039695 lactobacillus acidophilus Drugs 0.000 claims abstract description 10
- 241000901050 Bifidobacterium animalis subsp. lactis Species 0.000 claims abstract description 9
- 229940009289 bifidobacterium lactis Drugs 0.000 claims abstract description 7
- 241000186000 Bifidobacterium Species 0.000 claims abstract description 5
- 239000000843 powder Substances 0.000 claims description 33
- 241000894006 Bacteria Species 0.000 claims description 31
- 239000007788 liquid Substances 0.000 claims description 28
- 238000000855 fermentation Methods 0.000 claims description 16
- 230000004151 fermentation Effects 0.000 claims description 16
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 12
- 235000011389 fruit/vegetable juice Nutrition 0.000 claims description 7
- 235000015193 tomato juice Nutrition 0.000 claims description 7
- 235000005979 Citrus limon Nutrition 0.000 claims description 6
- 244000131522 Citrus pyriformis Species 0.000 claims description 6
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 6
- 229920000881 Modified starch Polymers 0.000 claims description 6
- 239000004368 Modified starch Substances 0.000 claims description 6
- 229930006000 Sucrose Natural products 0.000 claims description 6
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 6
- 229930003268 Vitamin C Natural products 0.000 claims description 6
- 235000019426 modified starch Nutrition 0.000 claims description 6
- 239000005720 sucrose Substances 0.000 claims description 6
- 235000019154 vitamin C Nutrition 0.000 claims description 6
- 239000011718 vitamin C Substances 0.000 claims description 6
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 claims description 5
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 claims description 5
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 5
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 5
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 5
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 5
- 238000002156 mixing Methods 0.000 claims description 5
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 3
- 229920002472 Starch Polymers 0.000 claims description 3
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 3
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 3
- 239000008107 starch Substances 0.000 claims description 3
- 235000019698 starch Nutrition 0.000 claims description 3
- 235000015203 fruit juice Nutrition 0.000 claims description 2
- 244000000626 Daucus carota Species 0.000 claims 1
- 235000002767 Daucus carota Nutrition 0.000 claims 1
- 239000008103 glucose Substances 0.000 abstract description 10
- 206010012601 diabetes mellitus Diseases 0.000 abstract description 8
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract description 7
- 102000017011 Glycated Hemoglobin A Human genes 0.000 abstract description 5
- 108010014663 Glycated Hemoglobin A Proteins 0.000 abstract description 5
- 230000000291 postprandial effect Effects 0.000 abstract description 4
- 238000002474 experimental method Methods 0.000 abstract description 3
- 230000002218 hypoglycaemic effect Effects 0.000 abstract description 3
- 150000002632 lipids Chemical class 0.000 abstract description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- 239000003814 drug Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 3
- 238000011081 inoculation Methods 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 235000015278 beef Nutrition 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 239000002054 inoculum Substances 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 241000251468 Actinopterygii Species 0.000 description 1
- 229940123208 Biguanide Drugs 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 102000004366 Glucosidases Human genes 0.000 description 1
- 108010056771 Glucosidases Proteins 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 101001076687 Lactobacillus gasseri Inulosucrase Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000227653 Lycopersicon Species 0.000 description 1
- 235000007688 Lycopersicon esculentum Nutrition 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 150000004283 biguanides Chemical class 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000013877 carbamide Nutrition 0.000 description 1
- 230000023852 carbohydrate metabolic process Effects 0.000 description 1
- 235000021256 carbohydrate metabolism Nutrition 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- YXVFQADLFFNVDS-UHFFFAOYSA-N diammonium citrate Chemical compound [NH4+].[NH4+].[O-]C(=O)CC(O)(C(=O)O)CC([O-])=O YXVFQADLFFNVDS-UHFFFAOYSA-N 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 229940099596 manganese sulfate Drugs 0.000 description 1
- 239000011702 manganese sulphate Substances 0.000 description 1
- 235000007079 manganese sulphate Nutrition 0.000 description 1
- SQQMAOCOWKFBNP-UHFFFAOYSA-L manganese(II) sulfate Chemical compound [Mn+2].[O-]S([O-])(=O)=O SQQMAOCOWKFBNP-UHFFFAOYSA-L 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002068 microbial inoculum Substances 0.000 description 1
- 239000003538 oral antidiabetic agent Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- -1 sulphonyl Ureas Chemical class 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
- A23P10/00—Shaping or working of foodstuffs characterised by the products
- A23P10/20—Agglomerating; Granulating; Tabletting
- A23P10/28—Tabletting; Making food bars by compression of a dry powdered mixture
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
- A23P10/00—Shaping or working of foodstuffs characterised by the products
- A23P10/30—Encapsulation of particles, e.g. foodstuff additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/113—Acidophilus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/145—Gasseri
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/173—Reuteri
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/51—Bifidobacterium
- A23V2400/531—Lactis
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Mycology (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
The invention discloses a kind of functional foods of probiotics preparation with effect of lowering blood sugar.It contains lactobacillus reuteri (Lactobacillus reuteri), Lactobacillus gasseri (Lactobacillus gasseri), lactobacillus acidophilus (Lactobacillusacidophilus) and bifidobacterium lactis (Bifidobacterium lactics).The functional food of probiotics preparation with effect of lowering blood sugar of the invention the experiment proved that, have the effect of significant hypoglycemic (reducing morning fasting blood-glucose, postprandial 2 hours blood glucose and glycosylated hemoglobin ratio) on obese model, diabetic and effectively control blood lipid.
Description
Technical field
The invention belongs to probiotics field of functional food, and in particular to a kind of probiotics preparation with effect of lowering blood sugar
Functional food.
Background technique
In recent years, the research in terms of microbial flora obtains progress with rapid changepl. never-ending changes and improvements, and the mankind are for microbial flora and people
There has also been more comprehensive understanding for close relation between body specified disease especially chronic disease.Diabetes are a kind of common
Metabolic disturbance diseases, it also easily causes other serious acute and chronic complication, seriously threatens other than causing carbohydrate metabolism disturbance
Health.It was reported that there is type 2 diabetic patient 1.3 hundred million in the current whole world, wherein China is up to 40,000,000 people, it is predicted that the year two thousand twenty,
The whole world will increase to 2.5 hundred million people.At present in the treatment of diabetes in addition to insulin injection, main oral hypoglycemic drug, such as sulphonyl
Ureas, biguanides and glucosidase inhibitor etc., but these drugs are larger to organ injuries such as liver, kidney and gastrointestinal tracts.
Find without or side effect it is lighter treatment diabetes medicament substitute become study emphasis, especially from probiotics or its generation
It thanks to the microbial inoculum formula that selection in product has function of reducing blood sugar, becomes the Main way of current diabetes medicament development.
Summary of the invention
The object of the present invention is to provide a kind of functional foods of probiotics preparation with effect of lowering blood sugar.
The functional food of probiotics preparation with effect of lowering blood sugar of the invention, contains lactobacillus reuteri
(Lactobacillus reuteri), Lactobacillus gasseri (Lactobacillusgasseri), lactobacillus acidophilus
(Lactobacillusacidophilus) and bifidobacterium lactis (Bifidobacterium lactics).
Liquid preparation, bacterium powder preparation can be made in the functional food of the probiotics preparation with effect of lowering blood sugar
Or bacterium tablet preparation.
The functional food be by lactobacillus reuteri bacterium mud, Lactobacillus gasseri bacterium mud, lactobacillus acidophilus bacterium mud and
Bifidobacterium lactis bacterium mud mixes according to cfu ratio 1:1:1:1, then liquid preparation is made with Mixed Microbes mud.The liquid preparation is
Mixing bacterium mud is added in the blended fruit juice of tomato juice and lemon juice, liquid preparation is mixed to get.Total thallus in liquid preparation
Concentration control is 109cfu/ml。
The functional food is by lactobacillus reuteri, Lactobacillus gasseri, lactobacillus acidophilus and bifidobacterium lactis
Fermentation liquid is mixed by cfu ratio 1:1:1:1, separating thallus and fermentation liquid, and thallus, which is lyophilized, is made thallus freeze-dried powder, and thallus freeze-dried powder is used
In preparation bacterium powder preparation or bacterium powder tablet.
The bacterium powder preparation be by fermentation liquid be concentrated 10 times after, it is solvable by every 100ml concentrated broth and trehalose 5g
Property starch 10g, oligofructose 10g, microcrystalline cellulose 30g, sucrose 10g, vitamin C 5g, modified starch 5g, maltose 5g and bacterium
Body freeze-dried powder 20g is uniformly mixing to obtain bacterium powder preparation.
The bacterium powder tablet is every thallus freeze-dried powder 20g, adds sucrose 10g, vitamin C 5g, modified starch 30g, malt
Sugared 5g, carrotene 5g, oligofructose 5g, microcrystalline cellulose 20g are uniformly mixed, tabletted, obtain bacterium powder tablet.
Advantage of the invention:
1. probiotics used in the present invention is the probiotics in country's addition catalogue, the characteristic with high foodsafety.
2. the present invention is by being not less than 1,000,000,000 (109Cfu/g (ml)) probiotics and its fermentating metabolism product be composed,
It is a kind of probiotics with hypoglycemic and lipid-reducing function.
3. the functional food of the probiotics preparation with effect of lowering blood sugar of the invention the experiment proved that, in fat mould
There is significant hypoglycemic (reducing morning fasting blood-glucose, postprandial 2 hours blood glucose and glycosylated hemoglobin ratio) in type, diabetic
With the effect of effective control blood lipid.
Detailed description of the invention:
Fig. 1 is the 1st week-the 16th week, weekly blood glucose average measurement；
Fig. 2 is-the 16 week the 1st week, postprandial two hours blood sugar detection values；
Fig. 3 is glycosylated hemoglobin measured value.
Specific embodiment:
The following examples are further illustrations of the invention, rather than limiting the invention.
Embodiment 1:
1. liquid preparation preparation method:
A, strain:
A, (Lactobacillus reuteri, the U.S., ATCC PTA 6475 are bought from the U.S. lactobacillus reuteri
ATCC collection)；
B, (U.S. Lactobacillusgasseri is bought from Swanson Health Products) Lactobacillus gasseri；
C, (14 U.S. LactobacillusacidophilusLa is bought from Jarrow lactobacillus acidophilus
Formulas)；
D, (U.S. Bifidobacterium lacticsBl-04 is bought from Jarrow Formulas) bifidobacterium lactis.
B, fermentation medium (modified MRS culture medium)
The configuration method of every 1000ml fermentation medium is as follows: 10 grams of beef protein powder, 10 grams of peptone, yeast are leached
5 grams of juice powder, 10 grams of glucose, 10 grams of lactose, 5 grams of sodium acetate, 2 grams of dibasic ammonium citrate, 0.1 gram of Tween 80,0.58 gram of magnesium sulfate,
0.28 gram of manganese sulfate, 5 grams of ammonium sulfate, 10 grams of calcium carbonate, 10 grams of oligofructose, tomato juice 200ml mixing, then plus aquae destillata extremely
1000ml adjusts pH6.2~6.4, with pressure cooker in 118 DEG C of sterilizing 15min.
The beef protein powder and Yeast diffusion juice powder is commercially available commodity, and tomato juice is made products.
Tomato juice: tomato chopping is added mass ratio 1:1 and is added to the water, boil 20 minutes, filters off residue, and supernatant is
Tomato juice.
Lemon juice: lemon chopping is added mass ratio 1:1 and is added to the water, boil 20 minutes, filters off residue, and supernatant is
Lemon juice.
Lactobacillus reuteri, Lactobacillus gasseri, lactobacillus acidophilus and bifidobacterium lactis are inoculated into 10ml fermentation training respectively
Support in base, logical nitrogen when inoculation, 37 DEG C stationary culture 16-24 hours, then the inoculum concentration of example 1% is inoculated by volume again
In 1000ml culture medium, logical nitrogen when inoculation, 37 DEG C stationary culture 16-24 hours, the then inoculum concentration of example 1% by volume again
Be inoculated into the fermentor of the fermentation medium containing 1000L, logical nitrogen when inoculation, 37 DEG C stationary culture 16-24 hours, fermented
Liquid.
Fermentation liquid plate-frame filtering, removes clear liquid, and residual current matter bacterium mud is bacterium mud, gives over to and compound in next step.
Lemon juice and tomato juice 1:1 in mass ratio are mixed, compound bacterium mud is then added, is mixed to get liquid preparation, liquid
Total cell concentration control is 10 in body preparation9cfu/ml。
The compound bacterium mud is by lactobacillus reuteri bacterium mud, Lactobacillus gasseri bacterium mud, lactobacillus acidophilus bacterium mud and cream
Bifidobacterium bacterium mud is mixed to get according to cfu ratio 1:1:1:1.
2. bacterium powder preparation preparation method:
Each fermentation liquid in step 1 is mixed by cfu ratio 1:1:1:1, wherein total strain number is calculated and counts, centrifuge separation
Thallus and fermentation liquid.Fermentation liquid concentration, thallus freeze-drying obtain thallus freeze-dried powder.Wherein, fermentation liquid concentration is by 1L fermentation liquid
Rotation is concentrated by evaporation to 100ml at 50~70 DEG C, then with trehalose 5g, soluble starch 10g, oligofructose 10g, crystallite
Cellulose 30g, sucrose 10g, vitamin C 5g, modified starch 5g, maltose 5g and thallus freeze-dried powder 20g are uniformly mixing to obtain bacterium
Powder preparation dispenses capsule, solid 1g in capsule, and total bacteria count mesh is no less than 10 in bacterium powder preparation9cfu/g。
3. bacterium tablet preparation preparation method:
Thallus freeze-dried powder 20g in above-mentioned 2 adds sucrose 10g, vitamin C 5g, modified starch 30g, maltose 5g, Hu Luo
Bu Su 5g, oligofructose 5g, microcrystalline cellulose 20g are uniformly mixed, tabletted, every 1g, tablet bacteria concentration 109cfu/g。
4, diabetes blood glucose controls experiment:
By the 16th week since the 1st week, patient takes 100 milliliters of liquid preparation of step 1 preparation every afternoon
(109cfu/ml).Period cuts out drug, and regular Hospital Physical Examination measures finger tip blood daily, takes within one week an average value.
Blood sugar detection: finger tip blood measures blood glucose meter (fish dive board pleases trendy 306 blood glucose meter of quasi- II type).
Glycosylated hemoglobin: Nanfang Hospital's outpatient service result of laboratory test, as a result as shown in Figure 1-3, after taking as can be seen from Figure 1
Fasting blood-glucose is decreased obviously within first week to the 16th week, and the 1st week to the 16th week as can be seen from Figure 2, postprandial blood sugar was decreased obviously,
Glycosylated hemoglobin as can be seen from Figure 3 obviously dropped to 7.4 by 11 in 4 months.
Claims (8)
1. a kind of functional food of the probiotics preparation with effect of lowering blood sugar, which is characterized in that contain lactobacillus reuteri
(Lactobacillus reuteri), Lactobacillus gasseri (Lactobacillus gasseri), lactobacillus acidophilus
(Lactobacillusacidophilus) and bifidobacterium lactis (Bifidobacterium lactics).
2. the functional food of the probiotics preparation according to claim 1 with effect of lowering blood sugar, which is characterized in that institute
The functional food for the probiotics preparation with effect of lowering blood sugar stated is liquid preparation, bacterium powder preparation or bacterium tablet preparation.
3. the functional food of the probiotics preparation according to claim 2 with effect of lowering blood sugar, which is characterized in that institute
Total cell concentration control is 10 in liquid preparation, bacterium powder preparation or the bacterium tablet preparation stated9cfu/ml。
4. the functional food of the probiotics preparation according to claim 1 with effect of lowering blood sugar, which is characterized in that institute
The functional food stated is by lactobacillus reuteri bacterium mud, Lactobacillus gasseri bacterium mud, lactobacillus acidophilus bacterium mud and bifidobacterium lactis
Bacterium mud mixes according to cfu ratio 1:1:1:1, then liquid preparation is made with Mixed Microbes mud.
5. the functional food of the probiotics preparation according to claim 4 with effect of lowering blood sugar, which is characterized in that institute
The liquid preparation stated is will to mix bacterium mud to be added in the blended fruit juice of tomato juice and lemon juice, is mixed to get liquid preparation.
6. the functional food of the probiotics preparation according to claim 2 or 3 with effect of lowering blood sugar, feature exist
In the functional food is by the fermentation liquid of lactobacillus reuteri, Lactobacillus gasseri, lactobacillus acidophilus and bifidobacterium lactis
It is mixed by cfu ratio 1:1:1:1, separating thallus and fermentation liquid, thallus, which is lyophilized, is made thallus freeze-dried powder, and thallus freeze-dried powder is used to prepare
Bacterium powder preparation or bacterium powder tablet.
7. the functional food of the probiotics preparation according to claim 6 with effect of lowering blood sugar, which is characterized in that institute
The bacterium powder preparation stated is after fermentation liquid is concentrated 10 times, by every 100ml concentrated broth and trehalose 5g, soluble starch 10g,
Oligofructose 10g, microcrystalline cellulose 30g, sucrose 10g, vitamin C 5g, modified starch 5g, maltose 5g and thallus freeze-dried powder
20g is uniformly mixing to obtain bacterium powder preparation.
8. the functional food of the probiotics preparation according to claim 6 with effect of lowering blood sugar, which is characterized in that institute
The bacterium powder tablet stated is every thallus freeze-dried powder 20g, adds sucrose 10g, vitamin C 5g, modified starch 30g, maltose 5g, carrot
Plain 5g, oligofructose 5g, microcrystalline cellulose 20g are uniformly mixed, tabletted, obtain bacterium powder tablet.
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910315091.0A CN109998113A (en) | 2019-04-18 | 2019-04-18 | A kind of functional food of the probiotics preparation with effect of lowering blood sugar |
| CN202010098967.3A CN111084385A (en) | 2019-04-18 | 2020-02-18 | Functional food of probiotic preparation with blood sugar reducing effect |
| PCT/CN2020/085252 WO2020211831A1 (en) | 2019-04-18 | 2020-04-17 | Functional food of probiotic preparation having blood glucose lowering effect |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910315091.0A CN109998113A (en) | 2019-04-18 | 2019-04-18 | A kind of functional food of the probiotics preparation with effect of lowering blood sugar |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN109998113A true CN109998113A (en) | 2019-07-12 |
Family
ID=67172891
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910315091.0A Withdrawn CN109998113A (en) | 2019-04-18 | 2019-04-18 | A kind of functional food of the probiotics preparation with effect of lowering blood sugar |
| CN202010098967.3A Pending CN111084385A (en) | 2019-04-18 | 2020-02-18 | Functional food of probiotic preparation with blood sugar reducing effect |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010098967.3A Pending CN111084385A (en) | 2019-04-18 | 2020-02-18 | Functional food of probiotic preparation with blood sugar reducing effect |
Country Status (2)
| Country | Link |
|---|---|
| CN (2) | CN109998113A (en) |
| WO (1) | WO2020211831A1 (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020211831A1 (en) * | 2019-04-18 | 2020-10-22 | 广东省微生物研究所（广东省微生物分析检测中心） | Functional food of probiotic preparation having blood glucose lowering effect |
| CN113197313A (en) * | 2020-09-02 | 2021-08-03 | 内蒙古蒙牛乳业（集团）股份有限公司 | Probiotic composition with functions of improving insulin resistance and fasting blood glucose and preparation method thereof |
| CN114480228A (en) * | 2022-04-15 | 2022-05-13 | 广东省科学院微生物研究所(广东省微生物分析检测中心) | Probiotics for relieving metabolic syndrome, metabolite formula and application thereof |
| CN114984058A (en) * | 2022-04-15 | 2022-09-02 | 广东省科学院微生物研究所(广东省微生物分析检测中心) | Application of probiotic and metabolite (metazoan) formula thereof in preparation of product for relieving colorectal inflammation |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114196562B (en) | 2020-09-29 | 2023-02-03 | 青岛蔚蓝生物股份有限公司 | Bacillus coagulans with blood sugar reducing effect and application thereof |
| TWI777475B (en) * | 2021-03-30 | 2022-09-11 | 豐華生物科技股份有限公司 | Treatment of type 1 diabetes mellitus with a combination of lactic acid bacteria strains |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2808024T3 (en) * | 2009-06-19 | 2019-09-30 | Dupont Nutrition Biosciences Aps | Bifidobacteria for treating congestive heart failure |
| US8298526B2 (en) * | 2010-06-02 | 2012-10-30 | Genmont Biotech Inc. | Lactobacillus strain, composition and use thereof for improving the syndrome of diabetes and complication thereof |
| CN102274245B (en) * | 2010-06-09 | 2014-06-11 | 景岳生物科技股份有限公司 | Novel lactacidophilus, composition thereof and use thereof in preparation of medicines for relieving diabetes mellitus and complications |
| CN104887716A (en) * | 2014-03-07 | 2015-09-09 | 景岳生物科技股份有限公司 | Lactobacillus reuteri GMNL-89 composition for treating type II diabetes mellitus and use thereof |
| CN107156587A (en) * | 2017-06-05 | 2017-09-15 | 北京天宝瑞健康科技有限公司 | Active probiotic solid beverage and its treatment diabetes B in apply |
| CN108783169A (en) * | 2018-06-25 | 2018-11-13 | 汉臣氏（沈阳）儿童制品有限公司 | A kind of tetrad probiotics solid beverage and preparation method thereof |
| CN109481510A (en) * | 2018-10-11 | 2019-03-19 | 张军毅 | It is a kind of to help to improve diabetes B and its synbiotic compound preparation of complication and preparation method thereof |
| CN109998113A (en) * | 2019-04-18 | 2019-07-12 | 广东省微生物研究所（广东省微生物分析检测中心） | A kind of functional food of the probiotics preparation with effect of lowering blood sugar |
-
2019
- 2019-04-18 CN CN201910315091.0A patent/CN109998113A/en not_active Withdrawn
-
2020
- 2020-02-18 CN CN202010098967.3A patent/CN111084385A/en active Pending
- 2020-04-17 WO PCT/CN2020/085252 patent/WO2020211831A1/en active Application Filing
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020211831A1 (en) * | 2019-04-18 | 2020-10-22 | 广东省微生物研究所（广东省微生物分析检测中心） | Functional food of probiotic preparation having blood glucose lowering effect |
| CN113197313A (en) * | 2020-09-02 | 2021-08-03 | 内蒙古蒙牛乳业（集团）股份有限公司 | Probiotic composition with functions of improving insulin resistance and fasting blood glucose and preparation method thereof |
| CN113197313B (en) * | 2020-09-02 | 2023-10-27 | 内蒙古蒙牛乳业（集团）股份有限公司 | Probiotic composition with effects of improving insulin resistance and fasting blood glucose and preparation method thereof |
| CN114480228A (en) * | 2022-04-15 | 2022-05-13 | 广东省科学院微生物研究所(广东省微生物分析检测中心) | Probiotics for relieving metabolic syndrome, metabolite formula and application thereof |
| CN114984058A (en) * | 2022-04-15 | 2022-09-02 | 广东省科学院微生物研究所(广东省微生物分析检测中心) | Application of probiotic and metabolite (metazoan) formula thereof in preparation of product for relieving colorectal inflammation |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2020211831A1 (en) | 2020-10-22 |
| CN111084385A (en) | 2020-05-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN109998113A (en) | A kind of functional food of the probiotics preparation with effect of lowering blood sugar | |
| CN108157973B (en) | Probiotic composition with beneficial glycolipid metabolism function and preparation and application thereof | |
| TWI709374B (en) | Use of food composition and pharmaceutical composition with strains of lactic acid bacteria for modulating blood glucose | |
| CN103127202B (en) | Utilize the manufacture method of the rhodiola fermentation product of Radix Ginseng Rubra and the tired compositions with improving motor capacity of the improvement containing this fermented product | |
| CN110150669B (en) | Probiotic composition suitable for diabetic patients and application thereof | |
| CN109481510A (en) | It is a kind of to help to improve diabetes B and its synbiotic compound preparation of complication and preparation method thereof | |
| CN113308421B (en) | Lactobacillus plantarum BUFX and application thereof in metabolic syndrome | |
| CN1709409B (en) | Anti-tumor agent, beverages and foods using the same, and a process for manufacturing the anti-tumor agent | |
| CN105595163A (en) | Health preserving composition and application thereof | |
| TWI719549B (en) | Prebiotic composition for promoting growth of akkermansia muciniphila | |
| CN108795823B (en) | It is a kind of improve women pregnant and lying-in women's intestinal flora probiotics cultural method and application | |
| JP3902015B2 (en) | Manufacturing method of health nutrition food | |
| CN1928073A (en) | Combination fermentation process of clostridiumbutyricum and lactobacillus acidophilus | |
| CN111228316B (en) | Composite probiotics for improving diabetes | |
| CN115044507B (en) | Microbial composition for treating and/or preventing abnormal glycolipid metabolism and application thereof | |
| CN114617265B (en) | Application of inactivated lactobacillus casei IOB-P9 metancholia powder in aspect of reducing blood sugar | |
| CN113209141B (en) | Composition based on brown algae extract and lactobacillus reuteri and application thereof | |
| TWI667344B (en) | Lactobacillus reuteri strain GMNL-263 and composition thereof capable of improving hypertension | |
| US20230144246A1 (en) | Probiotic composition and its method for improving intestinal tract of subject in need thereof | |
| TWI817342B (en) | Prebiotic composition and uses thereof | |
| TWI835021B (en) | Probiotic composition and its use | |
| CN117356714A (en) | Prebiotic composition and its use in reducing blood pressure | |
| CN116548609A (en) | Prebiotic composition and use thereof | |
| CN102258505A (en) | Application of glucose lowering medicaments to preparing intestinal flora modulator | |
| CN113952420A (en) | Preparation method of blood sugar reducing essence by utilizing bifidobacterium lactis fermented composite traditional Chinese medicine extract |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20190712 |
|
| WW01 | Invention patent application withdrawn after publication |